Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics

• Published in: Scientific reports Vol. 8; no. 1; pp. 8537 - 13
• Main Authors: Han, Kun, Lang, Tingyuan, Zhang, Zhiqi, Zhang, Yi, Sun, Yongning, Shen, Zan, Beuerman, Roger W., Zhou, Lei, Min, Daliu
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.06.2018; Nature Publishing Group
• Subjects: 13/1; 13/95; 14/32; 38/89; 631/337; 631/80; 82/58; Cell proliferation; Cell self-renewal; Frizzled protein; Heparan sulfate; Humanities and Social Sciences; multidisciplinary; Prostate cancer; Proteomics; Science; Science (multidisciplinary); Stem cells; Transcription; Tumor suppressor genes; Up-regulation; Wnt protein
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-26761-2

The mechanisms underlying luteolin-induced inhibition of prostate cancer (PCa) stemness have remained elusive. Here, we report that luteolin suppresses PCa stemness through Wnt signaling by upregulation of FZD6 (frizzled class receptor 6). Luteolin inhibits PCa cell proliferation, migration, self-renewal as well as the expression of prostate cancer stem cell markers in vitro . Through iTRAQ-based quantitative proteomics study, we identified 208 differentially expressed proteins in luteolin-treated PC-3 cells. Subsequent mechanistic analysis revealed that luteolin inhibits Wnt signaling by transcriptional upregulation of FZD6, and thereby suppressing the stemness of PCa cells. Furthermore, we identified FZD6 as a tumor suppressor that can abolish PCa stemness. In summary, our findings demonstrate that suppression of Wnt signaling by upregulation of FZD6 is a mechanism underlying luteolin-induced inhibition of PCa stemness. Our work suggests a new therapeutic strategy against human prostate cancer caused by aberrant activation of Wnt signaling.